According to the Tufts Center for the Study of Drug Development, the global vaccine market was estimated to be $33.1 billion in 2014 and is projected to grow to more than $40.0 billion by 2020.
In this rapidly growing market, vaccines administered by oral tablet rather than by injection could dramatically improve patient acceptance and increase vaccination rates. Vaxart stands at the leading edge of developing a new generation of vaccines, poised to benefit public health by protecting large populations against infectious diseases.
Many important pathogens still need an effective vaccine, and an ever-growing risk from newly-emerging pathogens demands continued vigilance and technologies to respond rapidly.
Vaxart is developing a range of oral recombinant vaccines based on our proprietary vector-adjuvant platform. All Vaxart vaccines are administered by tablets that are easy to store, distribute and administer.
Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Our vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. This is an important feature that could be instrumental in increasing vaccination rates and helping maximize the success of large vaccination campaigns for targets such as influenza, norovirus and respiratory syncytial virus (RSV).